G01N 2333/90688
Acting on other nitrogen compounds as donors
Official title: acting on other nitrogen compounds as donors (1.7)
G01N2333/90688 (Acting on other nitrogen compounds as donors) appears on 13 US grants and 18 published applications in this corpus.
Search patents in G01N- Granted patents
- 13
- Published applications
- 18
- Assignees
- 13
- Inventors
- 26
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 2 |
| 2016 | 2 | 2 |
| 2017 | 1 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 2 | 3 |
| 2024 | 1 | 1 |
| 2025 | 1 | 3 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy30 Jun 2026US 12,669,498 B2Horizon Therapeutics USA, Inc.
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy24 Feb 2026US 12,560,596 B2Amgen Inc.
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy7 Jan 2025US 12,188,927 B2Horizon Therapeutics USA, Inc.
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy14 May 2024US 11,982,670 B2Horizon Therapeutics USA, Inc.
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy2 May 2023US 11,639,927 B2Horizon Therapeutics USA, Inc.
- Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy30 Apr 2026US 2026/0118349 A1Horizon Therapeutics USA, Inc.
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy22 Jan 2026US 2026/0023073 A1Horizon Therapeutics USA, Inc.
- Smart chemo-enzymatic color change label and expiration date of food, pharmaceutical, and biological products11 Sep 2025US 2025/0283143 A1
- Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy17 Jul 2025US 2025/0231181 A1Horizon Therapeutics USA, Inc.
- Combinatorial high-throughput screening of complex polymeric enzyme immobilization supports19 Jun 2025US 2025/0198980 A1The Regents of the University of Colorado, a body corporate
Most cited
By later US patents
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy33US 9,377,454 B2Crealta Pharmaceuticals LLC · 2016
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy13US 10,139,399 B2Horizon Pharma Rheumatology LLC · 2018
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy13US 10,823,727 B2Horizon Pharma Rheumatology LLC · 2020
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy9US 11,639,927 B2Horizon Therapeutics USA, Inc. · 2023
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy6US 11,598,767 B2Horizon Therapeutics USA, Inc. · 2023